The FDA has classified as Class II an ongoing recall of carbamazepine tablets USP 200 mg distributed by Golden State Medical Supply, in 1000-count and 100-count bottles under NDC 51407-215-10 and 51407-215-01. The stated reason is a manufacturing deviation from current good manufacturing practice, presenting as black specks in the tablets. The classification was posted on 26 August 2026.
Read the classification for what it is. Class II means exposure may cause temporary or medically reversible harm, with serious injury unlikely — this is a product quality defect, not a safety communication about carbamazepine, and it says nothing about the drug's efficacy or its known risks. No batch is being described as sub-potent.
The part that matters clinically is continuity. Carbamazepine is one of the drugs where an unplanned switch of manufacturer, or a gap in supply, can matter to seizure control, and a patient who notices specks and simply stops taking the tablets is at more risk from the interruption than from the specks. This is a United States distribution recall naming US codes and a US distributor; it carries no statement about product supplied in India, and the Indian regulatory position on these lots is not addressed by it.
- If a patient on carbamazepine reports discoloured or speckled tablets, tell them not to stop the drug while a replacement is arranged.
- Confirm the supply route before reassuring — the recall names US NDC codes and a US distributor only.
- Where a switch of manufacturer is unavoidable, warn about breakthrough seizures and consider a level if the patient is close to the therapeutic margin.
- Class II is a quality defect classification, not a new safety warning about carbamazepine.
- Record the batch number if a patient brings in an affected bottle.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for neurology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free